Bio‑Techne Corporation announced a partnership with the Wyss Center for Bio and Neuroengineering to develop an automated workflow that simultaneously detects RNA and protein in intact three‑dimensional tissue specimens. The collaboration combines Lunaphore’s spatial biology platform with the Wyss Center’s expertise in 3‑D translational research, aiming to deliver high‑resolution multi‑omic analysis of intact 3‑D samples.
The partnership does not yet disclose a specific development timeline or financial terms. Bio‑Techne’s leadership has indicated that the project will be a multi‑year effort, with early proof‑of‑concept milestones expected in the first half of 2026. The agreement also does not reveal investment amounts, revenue‑sharing arrangements, or key performance indicators, but the companies have committed to jointly defining success metrics such as assay throughput, data integration speed, and clinical validation timelines.
This move positions Bio‑Techne as a leader in next‑generation spatial biology tools. By extending its Lunaphore platform into 3‑D, the company can offer researchers a single, automated workflow that reduces the need for animal models and accelerates organoid research. The partnership is expected to broaden Bio‑Techne’s market reach, strengthen its competitive edge against rivals such as NanoString, 10x Genomics, and Illumina, and support the company’s $1.2 billion net‑sales run‑rate in fiscal 2025 and its 3,100‑person global workforce.
Matt McManus, President of Bio‑Techne’s Diagnostics and Spatial Biology Segment, said the collaboration “combines our RNA and protein detection expertise with Wyss Geneva’s leadership in 3‑D translational research, enabling new possibilities in preclinical modeling and accelerating the path from discovery to impact.” Dr. Stéphane Pages, Director of Neuroimaging at Wyss Geneva, added that “3‑D multi‑omics will greatly enhance spatial insights gathering in the future, with the power to transform how we understand biology.”
The partnership underscores Bio‑Techne’s strategic focus on expanding spatial biology capabilities into 3‑D, a move that aligns with the company’s broader goal of making spatial biology technologies more accessible and fostering innovation across the life‑sciences research community.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.